Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | $398K | $1.42M | $3.38M | $7.65M | $9.64M | $12.1M | $13.8M |
| Revenue growth | — | — | — | — | 256.0% | 138.7% | 126.0% | 26.0% | 25.2% | 14.3% |
| Gross profit | — | — | — | $59.9K | $486K | $1.27M | $4.57M | $5.44M | $8.36M | $10.6M |
| Gross margin | — | — | — | 15.0% | 34.3% | 37.6% | 59.7% | 56.5% | 69.3% | 76.6% |
| Operating income | — | — | — | — | — | — | -$16.7M | -$15.4M | -$8.83M | -$2.45M |
| Operating margin | — | — | — | — | — | — | -218.8% | -159.9% | -73.2% | -17.8% |
| Net income | -$7.28M | -$7.81M | -$8.62M | -$8.59M | -$11.1M | -$15.5M | -$29.1M | -$18.7M | -$14.1M | -$8.42M |
| Net margin | — | — | — | -2157.7% | -780.6% | -457.7% | -380.8% | -193.6% | -116.8% | -61.1% |
| EPS (diluted) | -$0.29 | -$0.30 | -$0.29 | -$0.26 | -$0.32 | -$0.44 | — | -$2.26 | -$1.66 | -$0.56 |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$2.38M | -$3.75M | -$4.87M | -$5.22M | -$7.86M | -$11.1M | -$15.2M | -$13.5M | -$6.69M | -$2.38M |
| Capital expenditures | — | — | — | — | — | — | $29.8K | — | — | — |
| Free cash flow | — | — | — | — | — | — | -$15.2M | — | — | — |
| Dividends paid | — | — | — | — | $180K | $603K | — | — | — | — |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $53.6K | $425K | $844K | $63.6K | $950K | $2.20M | $12.1M | $570K | $786K | $365K |
| Total assets | $67.5K | $474K | $929K | $491K | $2.00M | $4.44M | $16.7M | $6.51M | $5.94M | $5.64M |
| Total liabilities | $4.14M | $4.86M | $756K | $2.27M | $5.00M | $11.3M | $18.8M | $26.4M | $35.9M | $35.7M |
| Shareholders' equity | -$2.57M | -$4.38M | $173K | -$1.78M | -$3.00M | -$6.83M | -$2.14M | -$19.8M | -$31.5M | -$32.0M |
| Retained earnings | -$16.5M | -$18.3M | -$26.4M | -$35.0M | -$46.4M | -$62.8M | -$93.0M | -$113M | -$127M | -$139M |
| Shares (wtd avg diluted) | 17.1M | 18.1M | 23.7M | 31.0M | 32.6M | 37.5M | 45.4M | 8.66M | 8.99M | 21.5M |
Every figure is extracted from BIOTRICITY INC.’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.